SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/15/22 AIM ImmunoTech Inc. 10-Q 6/30/22 72:6M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: 10-Q Quarterly Report HTML 1.44M 2: EX-10.86 Material Contract HTML 25K 3: EX-10.87 Material Contract HTML 25K 4: EX-10.88 Material Contract HTML 22K 5: EX-31.1 Certification -- §302 - SOA'02 HTML 26K 6: EX-31.2 Certification -- §302 - SOA'02 HTML 25K 7: EX-32.1 Certification -- §906 - SOA'02 HTML 21K 8: EX-32.2 Certification -- §906 - SOA'02 HTML 20K 14: R1 Cover HTML 72K 15: R2 Consolidated Balance Sheets (Unaudited) HTML 103K 16: R3 Consolidated Balance Sheets (Unaudited) HTML 35K (Parenthetical) 17: R4 Consolidated Statements of Comprehensive Loss HTML 93K (Unaudited) 18: R5 Consolidated Statements of Changes in HTML 58K Stockholders' Equity (Unaudited) 19: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 116K 20: R7 Business and Basis of Presentation HTML 34K 21: R8 Net Loss Per Share HTML 24K 22: R9 Equity-Based Compensation HTML 148K 23: R10 Marketable Securities HTML 49K 24: R11 Accrued Expenses HTML 34K 25: R12 Property and Equipment, net HTML 37K 26: R13 Patents HTML 41K 27: R14 Stockholders? Equity HTML 65K 28: R15 Cash and Cash Equivalents HTML 23K 29: R16 Recent Accounting Pronouncements HTML 22K 30: R17 Fair Value HTML 164K 31: R18 Financing Obligation Arising from Sale Leaseback HTML 28K Transaction 32: R19 Leases HTML 55K 33: R20 Research, Consulting and Supply Agreements HTML 31K 34: R21 Subsequent Events HTML 25K 35: R22 Equity-Based Compensation (Tables) HTML 147K 36: R23 Marketable Securities (Tables) HTML 48K 37: R24 Accrued Expenses (Tables) HTML 32K 38: R25 Property and Equipment, net (Tables) HTML 33K 39: R26 Patents (Tables) HTML 41K 40: R27 Fair Value (Tables) HTML 146K 41: R28 Leases (Tables) HTML 31K 42: R29 Business and Basis of Presentation (Details HTML 21K Narrative) 43: R30 Net Loss Per Share (Details Narrative) HTML 24K 44: R31 Schedule of Stock Option Activity (Details) HTML 80K 45: R32 Schedule of Unvested Stock Option Activity HTML 61K (Details) 46: R33 Equity-Based Compensation (Details Narrative) HTML 26K 47: R34 Schedule of Available for Sale (Details) HTML 25K 48: R35 Schedule of Equity Securities (Details) HTML 26K 49: R36 Marketable Securities (Details Narrative) HTML 25K 50: R37 Schedule of Accrued Expenses (Details) HTML 30K 51: R38 Schedule of Property and Equipment (Details) HTML 32K 52: R39 Property and Equipment, net (Details Narrative) HTML 24K 53: R40 Schedule of Patents, Trademark Rights (Details) HTML 27K 54: R41 Schedule of Amortization of Patents and Trademarks HTML 35K (Details) 55: R42 Patents (Details Narrative) HTML 23K 56: R43 Stockholders? Equity (Details Narrative) HTML 157K 57: R44 Schedule of Assumptions to Estimate Fair Value of HTML 63K Warrants (Details) 58: R45 Schedule of Range of Probabilities (Details) HTML 26K 59: R46 Schedule of Assets and Liabilities Measured at HTML 34K Fair Value on a Recurring Basis (Details) 60: R47 Schedule of Changes in Level 3 Liabilities HTML 26K Measured at Fair Value on a Recurring Basis (Details) 61: R48 Schedule of Assets and Liabilities Measured at HTML 33K Fair Value on a NonRecurring Basis (Details) 62: R49 Schedule of Assets and Liabilities Measured at HTML 28K Fair Value on a NonRecurring Basis (Details) (Parenthetical) 63: R50 Fair Value (Details Narrative) HTML 31K 64: R51 Financing Obligation Arising from Sale Leaseback HTML 39K Transaction (Details Narrative) 65: R52 Schedule of Operating lease Future Payments HTML 34K (Details) 66: R53 Leases (Details Narrative) HTML 67K 67: R54 Research, Consulting and Supply Agreements HTML 41K (Details Narrative) 70: XML IDEA XML File -- Filing Summary XML 121K 68: XML XBRL Instance -- form10-q_htm XML 1.39M 69: EXCEL IDEA Workbook of Financial Reports XLSX 106K 10: EX-101.CAL XBRL Calculations -- aim-20220630_cal XML 155K 11: EX-101.DEF XBRL Definitions -- aim-20220630_def XML 475K 12: EX-101.LAB XBRL Labels -- aim-20220630_lab XML 887K 13: EX-101.PRE XBRL Presentations -- aim-20220630_pre XML 682K 9: EX-101.SCH XBRL Schema -- aim-20220630 XSD 130K 71: JSON XBRL Instance as JSON Data -- MetaLinks 309± 441K 72: ZIP XBRL Zipped Folder -- 0001493152-22-022600-xbrl Zip 266K
Exhibit 10.88
Termination Agreement
Further and pursuant to the Material Transfer and Research Agreement signed on April 1, 2020 and the Supplemental Extension agreement signed on May 21, 2021 due to expire on May 31, 2023, the Parties agreed pursuant to our last email communication to terminate the Agreement as of August 10, 2022.
AIM IMMUNOTECH, INC.
By: | /s/Peter W. Rodino | |
Date : | August 10, 2022 | |
Name: | Peter W. Rodino | |
Title : | General Counsel |
SHENZHEN SMOORE TECHNOLOGY LIMITED
By: | /s/Zhiqiang Shi | |
Date: | August 10, 2022 | |
Name: | Zhiqiang Shi | |
Title : | Global R&D Director (Smoore International) |
C:
This ‘10-Q’ Filing | Date | Other Filings | ||
---|---|---|---|---|
5/31/23 | ||||
Filed on: | 8/15/22 | |||
8/10/22 | ||||
For Period end: | 6/30/22 | |||
5/21/21 | 8-K | |||
4/1/20 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/19/24 AIM ImmunoTech Inc. S-1 6:628K M2 Compliance LLC/FA 4/01/24 AIM ImmunoTech Inc. 10-K 12/31/23 84:8.7M M2 Compliance LLC/FA 11/14/23 AIM ImmunoTech Inc. 10-Q 9/30/23 64:5.5M M2 Compliance LLC/FA 8/14/23 AIM ImmunoTech Inc. 10-Q 6/30/23 63:5.3M M2 Compliance LLC/FA 5/15/23 AIM ImmunoTech Inc. 10-Q 3/31/23 65:4.7M M2 Compliance LLC/FA 3/31/23 AIM ImmunoTech Inc. 10-K 12/31/22 87:8.7M M2 Compliance LLC/FA 11/14/22 AIM ImmunoTech Inc. 10-Q 9/30/22 75:5M M2 Compliance LLC/FA |